CADTH recommends medical abortion reimbursement

Statement of Vicki Saporta, President and CEO of the National Abortion Federation Canada on the Canadian Agency for Drugs and Technologies in Health (CADTH) recommendation on Mifegymiso:

We are pleased that CADTH has recommended that mifepristone and misoprostol be reimbursed for medical abortion care. CADTH’s recommendation will help make medical abortion care more widely accessible to women throughout Canada.

Mifepristone and misoprostol are on the World Health Organization’s list of essential medications. A mifepristone/misoprostol regimen is the gold standard in medical abortion care. We encourage all provincial and territorial ministers of health to follow the lead of New Brunswick and provide universal coverage for medical abortion care using mifepristone and misoprostol.

# # #

The National Abortion Federation (NAF) is the professional association of abortion providers. Our members include clinics, hospitals and physicians who together care for more than half the women who choose abortion in Canada each year. NAF Canada works to ensure safe, legal, and accessible abortion care, which promotes health and justice for women.

Share this Post